Oklo stock tumbles as Financial Times scrutinizes valuation
Director Tariq Musa of Guardant Health, Inc. (NASDAQ:GH) sold 116 shares of common stock on October 17, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $66.95, for a total transaction value of $7,766. The transaction comes as the stock trades near its 52-week high, having delivered an impressive 206% return over the past year. According to InvestingPro analysis, the stock appears to be fairly valued at current levels.
Following the transaction, Musa directly owns 7,725 shares of Guardant Health . The company, with a market capitalization of $8.16 billion, maintains strong liquidity with a current ratio of 3.71 and is scheduled to report earnings on October 29. For deeper insights into insider trading patterns and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Guardant Health, Inc. received approval from the U.S. Food and Drug Administration for its Guardant360 CDx blood test. This test will serve as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from Eli Lilly’s drug, Inluriyo. This development is expected to impact those with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer. Meanwhile, Bernstein SocGen Group has reiterated an Outperform rating with a $60 price target on Guardant Health following its 2025 Investor Day. JPMorgan also maintained its Overweight rating on the company, noting an update in Guardant Health’s 2028 financial targets, projecting approximately $2.2 billion in revenue. Guggenheim raised its price target on the stock to $67, citing recent product launches. Additionally, TD Cowen increased its price target to $72, maintaining a Buy rating, despite a slight decline in shares amid broader sector weakness.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.